Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009
Date:7/29/2009

ncluding Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AHIMA Enters Multinational Arena to Support HIM Worldwide Advancement
2. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
3. Arena Pharmaceuticals Announces Public Offering of Common Stock
4. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
5. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
6. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
7. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
8. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
9. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
10. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
11. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2009)...USNewswire/ -- A regional initiative launched in t...ess) in the Americas has substantially reduced the...denced by a 31% decrease in the number of individu...mic countries. Results were reported today at the...opical Medicine and Hygiene (ASTMH). ,, The re...
(Date:11/21/2009)...edentialing software company IntelliSoft Group is ...th Amerinet, Inc., the leading healthcare G.P.O. i...m quality care within the healthcare market. , ... ISG Group, LLC, doing business as IntelliSoft Gro...c., a leading national healthcare group purchasing...
(Date:11/21/2009)...dent and chief executive officer of the Alzheimer,... statement regarding the inclusion of cognitive im...ess for Medicare beneficiaries in "The Patien...s introduced last night: , .... Hall, president and chief executive officer of t...
(Date:11/20/2009)...nderstanding Brain Wiring and Diseases ,, WASHI...my Schmahmann, Professor of Neurology at Harvard M... General Hospital in Boston, on Thursday, November...w field of study called "Connectivity" at the laun...n is an award-winning leader in the field of the c...
(Date:11/20/2009)...re-USNewswire/ -- The United States Conference of ...l changes its health reform bill in order to keep ...ience protection on abortion, protect access to he...ions for adequate affordability. ,, The bishops...isappointment" that creates new and unacceptable f...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2
...dietary habits and increased weight in the middle ... of high calorie diet and employment of food as mo...the students//. Other factors such as selling food...hildren population are burdened with this curse of...
...HIV positive people of Mizo society to treat them ...eath. Malsawmdawnga who is the president of Mizora... press talk stating that even as the world is chan...ad bodies of AIDS patients in polytene bags before...
...ai spoke to the press about improvising the health...aid that the city needs more hospitals with ICUs//...ices, which are easily accessible by the public. ...inister Mr. Nitish Kumar is also having a keen int...
...ed for curtailing comparative advertisements, afte...ucers//. Suitable amendments should be made to the...n addition to other media and channels, and the Mo...roducts of a competitor are concerned. Comparative...
...pal gas leak tragedy was on Saturday 30 doctors of...resigned. The doctors wanted a pay hike. The...treatment daily. Run by a trust, the BMHRC was set...aintenance Act (ESMA) has been imposed on the juni...
...st bird flu to all its poultry birds and wild bird...ess program to farmers and villagers about the imp... the villagers to report immediately any doubtful ...lu and is an increased threat for mutation of the ...
Other Medicine News:Health News:Conditions Of The HIV/AIDS Patients In The Mizo Society 2
(Date:11/20/2009)..., , FRANKLIN LAKES, N.J., Nov. 20 /PRNewswi...) (NYSE: BDX ) today announced the completion of...Michigan-based company that develops and manufactu...tforms. ,, In May 2009, BD and HandyLab announc...mmercialize molecular assays on the HandyLab Jagua...
(Date:11/20/2009)..., , PRINCETON, N.J., Nov. 20 /PRNewswire-... SNGX) (Soligenix or the Company), formerly known ... company, announced today that it has formed a con...nce RiVax(TM) and other rapidly acting vaccines. S...tional Institute of Allergy and Infectious Disease...
(Date:11/19/2009)..., , BIRMINGHAM, Ala., Nov. 19 /PRNewswire...daq: BCRX ) today announced the pricing of a publ...k at $9.75 per share, resulting in gross proceeds ...fered by BioCryst pursuant to an effective shelf r...curities and Exchange Commission. BioCryst has al...
Breaking Medicine Technology:BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3WuXi PharmaTech Announces Second Quarter 2009 Results 13509 1WuXi PharmaTech Announces Second Quarter 2009 Results 13509 2WuXi PharmaTech Announces Second Quarter 2009 Results 13509 3WuXi PharmaTech Announces Second Quarter 2009 Results 13509 4WuXi PharmaTech Announces Second Quarter 2009 Results 13509 5WuXi PharmaTech Announces Second Quarter 2009 Results 13509 6WuXi PharmaTech Announces Second Quarter 2009 Results 13509 7WuXi PharmaTech Announces Second Quarter 2009 Results 13509 8WuXi PharmaTech Announces Second Quarter 2009 Results 13509 9WuXi PharmaTech Announces Second Quarter 2009 Results 13509 10WuXi PharmaTech Announces Second Quarter 2009 Results 13509 11WuXi PharmaTech Announces Second Quarter 2009 Results 13509 12WuXi PharmaTech Announces Second Quarter 2009 Results 13509 13WuXi PharmaTech Announces Second Quarter 2009 Results 13509 14WuXi PharmaTech Announces Second Quarter 2009 Results 13509 15WuXi PharmaTech Announces Second Quarter 2009 Results 13509 16VIVUS Reports Second Quarter 2009 Financial Results 54258 1VIVUS Reports Second Quarter 2009 Financial Results 54258 2VIVUS Reports Second Quarter 2009 Financial Results 54258 3VIVUS Reports Second Quarter 2009 Financial Results 54258 4VIVUS Reports Second Quarter 2009 Financial Results 54258 5VIVUS Reports Second Quarter 2009 Financial Results 54258 6VIVUS Reports Second Quarter 2009 Financial Results 54258 7Mesa Labs Reports Higher First Quarter Earnings 54256 1Mesa Labs Reports Higher First Quarter Earnings 54256 2Mesa Labs Reports Higher First Quarter Earnings 54256 3Mesa Labs Reports Higher First Quarter Earnings 54256 4Mesa Labs Reports Higher First Quarter Earnings 54256 5
...ebruary 26 ExonHit Therapeutics,(Alternext: ALEHT...EHT 0202,its lead compound in Alzheimer,s disease,...ase IIa trial assessing EHT 0202 in patients with,...ssful completion of patient enrolment for the Phas...elopment of EHT 0202, and,provides a clear timelin...
...cians at Northwestern Memorial are among the first...al natural orifice translumenal endoscopic surgery...thwestern Memorial Hospital successfully removed a...them the first in the Midwest and the third in the...technique, known as NOTES -- natural orifice trans...
Other Medicine Technology:ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 2ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 3ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 4Gallbladder Removal Through Vagina Offers Minimally Invasive Alternative 2Gallbladder Removal Through Vagina Offers Minimally Invasive Alternative 3
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: